Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry (2020)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1002/clc.23283
- Subjects: INFARTO DO MIOCÁRDIO; DOENÇAS CARDIOVASCULARES; FATORES DE RISCO; INCIDÊNCIA; ANÁLISE DE RISCO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Clinical cardiology
- ISSN: 0160-9289
- Volume/Número/Paginação/Ano: v. 43, n. 1, p. 24-32, 2020
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
POCOCK, Stuart J et al. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clinical cardiology, v. 43, n. 1, p. 24-32, 2020Tradução . . Disponível em: https://doi.org/10.1002/clc.23283. Acesso em: 28 dez. 2025. -
APA
Pocock, S. J., Brieger, D., Gregson, J., Chen, J. Y., Cohen, M. G., Goodman, S. G., et al. (2020). Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clinical cardiology, 43( 1), 24-32. doi:10.1002/clc.23283 -
NLM
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry [Internet]. Clinical cardiology. 2020 ; 43( 1): 24-32.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1002/clc.23283 -
Vancouver
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry [Internet]. Clinical cardiology. 2020 ; 43( 1): 24-32.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1002/clc.23283 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Anticoagulação e antiagregação plaquetária nas síndromes isquêmicas miocárdicas instáveis [Carta]
Informações sobre o DOI: 10.1002/clc.23283 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
